From discovery to approval A brief history of the compstatin family of complement C3 inhibitors

From discovery to approval : A brief history of the compstatin family of complement C3 inhibitors

Copyright © 2021 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 235(2022) vom: 01. Feb., Seite 108785
1. Verfasser: Mastellos, Dimitrios C (VerfasserIn)
Weitere Verfasser: Ricklin, Daniel, Sfyroera, Georgia, Sahu, Arvind
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Complement C3 Peptides, Cyclic compstatin pegcetacoplan TO3JYR3BOU
Beschreibung
Zusammenfassung:Copyright © 2021 Elsevier Inc. All rights reserved.
The FDA approval of pegcetacoplan (Empaveli), a PEGylated compstatin-based C3 therapeutic, as a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) marks a milestone in the history of complement drug discovery. Almost 15 years after the approval of the first complement-specific drug for PNH, the anti-C5 antibody eculizumab, a novel class of complement inhibitors with a distinct mechanism of action finally enters the clinic. This landmark decision broadens the spectrum of available complement therapeutics, offering patients with unmet clinical needs or insufficient responses to anti-C5 therapy an alternative treatment option with a broad activity profile. Here we present a brief historical account of this newly approved complement drug, consolidating its approval within the long research record of the compstatin family of peptidic C3 inhibitors
Beschreibung:Date Completed 23.02.2022
Date Revised 23.02.2022
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2021.108785